

# INITIAL CREDIT RATING REPORT DEWAN DRUGS



Ref. no.: FR/2023/033782

## Report Contents:


Particulars	Page
Rating Rationale	1
Entity Profile	2
Business Management	2
Business Analysis	2
Financial Position Analysis	3
Banking Relationship	4
Risk Factor Analysis	4
Rating Observation	5

## Key Snapshot:

BDT. In million

Particulars	2022	2021
Revenue	25.02	21.53
EBIT	1.76	1.02
Net Profit	1.75	1.02
Total Assets	13.57	13.46
Total Equity	11.95	11.43
Total debt	1.61	2.03
Net Profit Margin (%)	7.0	4.7
CCC (Days)	153	178
ICR (X)	332.24	194.28

Capital Structure  
(BDT. In million)



## Analysts:

**Mst. Irin Akter**  
irin@wasocreditrating.com

**Maharan Nasrin**  
maharan@wasocreditrating.com

SME Rating	Rating Notch	Outlook	Date of Declaration	Date of Expiration
	WCRSME3	Stable	19 September 2023	18 September 2024

**Methodology:** SME rating methodology published on the WCRCL website at [www.wasocreditrating.com](http://www.wasocreditrating.com)

## RATING RATIONALE

WCRCL has assigned WCRSME3' (pronounced as WASO Credit Rating Small and Medium Enterprise Three) rating under the SME Rating to Dewan Drugs (hereinafter referred as "DD" or "The Enterprise") based on its financial and other relevant qualitative and quantitative information up-to the date of the rating issuance.

The above rating has been assigned based on the fundamentals of the enterprise which includes:

- Long business experiences of the proprietor in the business
- Good business network
- Good profitability margin
- Low levered capital structure
- Comfortable interest coverage position

However, the above rating has been moderated to some extent due to some factors like:

- Low disclosure in the financial statements
- Tight liquidity position considering long cash conversion cycle
- No insurance coverage for the inventory in stock
- Manual accounting system

The SME rating implies that the enterprise is adjudged to above average credit quality.

WCRCL also viewed the enterprise with "Stable" outlook and believes that DD will be able to maintain its good fundamentals in the foreseeable future.

This rating may be revised in case of any extraordinary changes in line with the sponsor's equity investment, debt obligations, management, business operations and/or changes in any macro and micro factors in the economy.